AMN Healthcare Services (AMN) stock is back in focus after second quarter 2026 results came in ahead of guidance, alongside a return to profitability and fresh revenue expectations for the third quarter.

The latest earnings beat and guidance appear to have reinforced momentum in AMN Healthcare Services, with a 1-day share price return of 6.32% and a 7-day share price return of 11.98% adding to a 128.11% year to date share price return. However, the 5-year total shareholder return is still down 67.29%, suggesting recent optimism is building from a much weaker longer term base.

If strong moves in AMN have you rethinking where the next opportunity might be, this could be a useful moment to look across healthcare staffing and technology and review 44 healthcare AI stocks

AMN Healthcare Services now appears to be a solidly profitable staffing and technology business again, following a sharp share price rebound. The key question for investors is whether the current price already reflects that recovery.

Most Popular Narrative: 57% Overvalued

The most followed narrative for AMN Healthcare Services pegs fair value at $22, well below the last close at $34.49, which sets a cautious tone for valuation.

While consolidation among weaker competitors could present opportunities for AMN to gain market share in a fragmented industry, cost containment efforts by hospital systems, increasing bargaining power from provider consolidation, and ongoing legislative risk around healthcare funding and labor regulation all present risks that could further compress net margins and earnings in the coming years.

Want to see how this narrative gets to its fair value for AMN Healthcare Services? The key assumptions juggle falling revenue, changing margins and a tighter valuation multiple. The precise mix of these inputs is what drives that $22 figure.

Result: Fair Value of $22 (OVERVALUED)

However, there are still risks that could challenge this bearish AMN Healthcare Services narrative if they play out differently, including academic funding trends and immigration or visa policy shifts.

Another View On AMN Healthcare Services Valuation

The first narrative framed AMN Healthcare Services as 57% overvalued based on analyst assumptions about slower revenue and earnings. The SWS DCF model points in the opposite direction. At a share price of $34.49 and an estimated future cash flow value of $42.80, it signals the stock is trading below that cash flow estimate, or about 19.4% under fair value on this approach. For investors, the question is which set of assumptions feels more realistic for how AMN actually converts its current business into long term cash flows.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AMN Healthcare Services for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals around AMN Healthcare Services, this is a moment to look past headlines and test the data yourself. To weigh both the upside potential and the downside flags, start with the 2 key rewards and 3 important warning signs

Looking for more AMN Healthcare Services investment ideas?

If AMN Healthcare Services has your attention, do not stop with a single stock. Broader idea hunting often reveals opportunities you did not expect to find.

• Zero in on potential bargains and compare them with AMN by scanning 51 high quality undervalued stocks built from companies with strong fundamentals.
• Strengthen your focus on capital protection by checking 88 resilient stocks with low risk scores that aim to keep downside risk in check.
• Get ahead of the crowd by reviewing the screener containing 18 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.